Holen Sie sich die Stockscreener-App
34.68
1.64%
-0.62
Schlusskurs vom Vortag:
$35.30
Offen:
$35.31
24-Stunden-Volumen:
1.13M
Relative Volume:
0.56
Marktkapitalisierung:
$4.10B
Einnahmen:
$1.29B
Nettoeinkommen (Verlust:
$251.00M
KGV:
17.56
EPS:
1.9744
Netto-Cashflow:
$-193.86M
1W Leistung:
-5.83%
1M Leistung:
-15.30%
6M Leistung:
+6.11%
1J Leistung:
+45.39%
1-Tages-Spanne:
$34.63
$35.49
1-Wochen-Bereich:
$34.63
$36.81
52-Wochen-Spanne:
$22.22
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
34.72 | 4.46B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
18.01 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.08 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.51 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.80 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.06 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - Ad-hoc-news.de
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - Sahm
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - uk.finance.yahoo.com
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Exploring a 27% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV - MarketBeat
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - tradingview.com
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Indivior Pharmaceuticals Inc (INDV) Shares Surge 6.1% -- What GF Score of 75 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares - Stock Titan
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com Nigeria
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Indivior Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential - DirectorsTalk Interviews
Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - stocktitan.net
Supernus and Indivior to merge, forming $2.2B CNS drug company - Dealroom
Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan
Indivior Pharmaceuticals, Inc. 2026: Revenue $343M, EPS $0.98— 10-Q Summary - TradingView
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Indivior Falls as Investors Reposition Ahead of Second-Quarter Results - Quiver Quantitative
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook - Yahoo Finance
Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan
Indivior Pharmaceuticals Inc. R (E7P.MU) Q2 FY2026 & Merger earnings call transcript - Yahoo Finance
CNS-focused Supernus and Indivior agree merger terms - pharmaphorum
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):